PL3057595T3 - Skondensowane benzazepiny do leczenia jąkania - Google Patents

Skondensowane benzazepiny do leczenia jąkania

Info

Publication number
PL3057595T3
PL3057595T3 PL14854586T PL14854586T PL3057595T3 PL 3057595 T3 PL3057595 T3 PL 3057595T3 PL 14854586 T PL14854586 T PL 14854586T PL 14854586 T PL14854586 T PL 14854586T PL 3057595 T3 PL3057595 T3 PL 3057595T3
Authority
PL
Poland
Prior art keywords
stuttering
treatment
fused benzazepines
benzazepines
fused
Prior art date
Application number
PL14854586T
Other languages
English (en)
Inventor
Richard E. Chipkin
Original Assignee
Emalex Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emalex Biosciences, Inc. filed Critical Emalex Biosciences, Inc.
Publication of PL3057595T3 publication Critical patent/PL3057595T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL14854586T 2013-10-18 2014-10-17 Skondensowane benzazepiny do leczenia jąkania PL3057595T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892841P 2013-10-18 2013-10-18
PCT/US2014/061080 WO2015058053A1 (en) 2013-10-18 2014-10-17 Fused benzazepines for treatment of stuttering
EP14854586.6A EP3057595B1 (en) 2013-10-18 2014-10-17 Fused benzazepines for treatment of stuttering

Publications (1)

Publication Number Publication Date
PL3057595T3 true PL3057595T3 (pl) 2021-03-08

Family

ID=52828726

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14854586T PL3057595T3 (pl) 2013-10-18 2014-10-17 Skondensowane benzazepiny do leczenia jąkania

Country Status (18)

Country Link
US (1) US9949983B2 (pl)
EP (1) EP3057595B1 (pl)
JP (3) JP2016533374A (pl)
AU (1) AU2014337140B2 (pl)
CA (1) CA2927915C (pl)
CY (1) CY1123121T1 (pl)
DK (1) DK3057595T3 (pl)
ES (1) ES2805448T3 (pl)
HR (1) HRP20201152T1 (pl)
HU (1) HUE049848T2 (pl)
IL (1) IL245155B (pl)
LT (1) LT3057595T (pl)
MX (1) MX370612B (pl)
PL (1) PL3057595T3 (pl)
PT (1) PT3057595T (pl)
RS (1) RS60556B1 (pl)
SI (1) SI3057595T1 (pl)
WO (1) WO2015058053A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058696T2 (hu) 2012-07-12 2022-09-28 Emalex Biosciences Inc Fúzionált benzazepinek a turett-szindróma terápiájában
BR112019019242A2 (pt) 2017-03-30 2020-04-14 Jose Eduardo Penello Temporao composição multivitamínica para aprimoramento da fluência verbal, dimimuição dos sintomas da ansiedade de performance e seu método e preparação
KR102608479B1 (ko) * 2017-05-25 2023-12-01 글리테크 엘엘씨. Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법
US10786495B2 (en) * 2017-10-10 2020-09-29 The Regents Of The University Of California Vesicular monoamine transporter 2 inhibitors for treating stuttering
WO2020237247A1 (en) * 2019-05-23 2020-11-26 India Globalization Capital, Inc. Compositions and methods using cannabinoids for treating stammering/stutering and symptoms of tourette syndrome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477378A (en) 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US5302716A (en) 1986-01-16 1994-04-12 Schering Corporation Fused benzazepines
US4973586A (en) 1986-01-16 1990-11-27 Schering Corporation Fused benzazepines, compositions of, and medical use thereof
BE1005064A4 (nl) 1991-07-03 1993-04-06 Asm Fico Tooling Buiginrichting.
GB9127306D0 (en) 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
DK0750616T3 (da) 1994-03-16 2001-07-23 Cenes Ltd Syreadditionssalte af 2,3,4,5-tetrahydro-1H-3-benzazapinforbindelser
IL135659A0 (en) * 1997-10-28 2001-05-20 Schering Corp Method of reducing craving in mammals
US6132724A (en) * 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2012033874A1 (en) 2010-09-10 2012-03-15 Chipkin Richard E Method of treating compulsive self-injurious behaviors
HUE058696T2 (hu) 2012-07-12 2022-09-28 Emalex Biosciences Inc Fúzionált benzazepinek a turett-szindróma terápiájában

Also Published As

Publication number Publication date
IL245155A0 (en) 2016-06-30
MX370612B (es) 2019-12-18
JP2016533374A (ja) 2016-10-27
NZ719103A (en) 2021-05-28
JP2021080288A (ja) 2021-05-27
AU2014337140B2 (en) 2020-01-30
PT3057595T (pt) 2020-07-31
EP3057595A1 (en) 2016-08-24
US9949983B2 (en) 2018-04-24
IL245155B (en) 2020-07-30
HUE049848T2 (hu) 2020-11-30
HRP20201152T1 (hr) 2020-10-30
EP3057595B1 (en) 2020-04-29
DK3057595T3 (da) 2020-08-10
US20160271141A1 (en) 2016-09-22
RS60556B1 (sr) 2020-08-31
JP7245509B2 (ja) 2023-03-24
CA2927915C (en) 2021-10-26
LT3057595T (lt) 2020-08-10
MX2016005030A (es) 2017-01-23
JP2019147843A (ja) 2019-09-05
WO2015058053A1 (en) 2015-04-23
SI3057595T1 (sl) 2020-09-30
AU2014337140A1 (en) 2016-05-12
EP3057595A4 (en) 2017-06-07
ES2805448T3 (es) 2021-02-12
CA2927915A1 (en) 2015-04-23
CY1123121T1 (el) 2021-10-29

Similar Documents

Publication Publication Date Title
SG11201506876XA (en) Modification of polypeptides
AU352456S (en) Process tube
GB2519934B (en) Improved shisha
HK1216429A1 (zh) 用於純化芳基硫酸酯酶 的方法
GB2516725B (en) Neck Orthosis
IL245379A0 (en) Heterocyclic n-acylamino compounds
SG11201505204VA (en) Protein purification process
SG11201603028SA (en) Purification of proteins
EP3043813A4 (en) CLEANING CHIMERIC FVIII MOLECULES
IL245155B (en) Benzazepines are combined for the treatment of stuttering
EP3065944A4 (en) Modification of polyamides
EP2929915A4 (en) CULTURISM DEVICE
GB2539112B (en) Chlorination of sucrose-6-esters
GB201308466D0 (en) Improved process for treatment of minewater
IL244347A0 (en) n-acylamino heterocyclic compounds
ZA201601248B (en) Wheelchair
AU347055S (en) Jug
GB201303796D0 (en) Condom
GB201314581D0 (en) Purification
HK1217700A1 (zh) 多晶型物形式
GB2514324B (en) Modified tubular
GB201300649D0 (en) Cyclization
GB201301722D0 (en) Quantifcation of bacteria
GB201322366D0 (en) Chlorination of sucrose-6-esters
GB201314779D0 (en) Chlorination of sucrose-6-esters